A causal link between chronic spontaneous urticaria and gut microbiota, with metabolic pathways potentially acting as ...

Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapiesEXTON, PA, May ...

Rilzabrutinib significantly alleviates itch and hives in patients with CSU unresponsive to H1-antihistamines, offering a potential new treatment option. The RILECSU trial demonstrated significant ...

When comparing the BLI/INO group to the chemotherapy group, the 2-year OS was 63% vs 31.2%, respectively, and the 2-year DFS was 49.6% vs 22.9%, respectively. Blinatumomab (BLI) and inotuzumab ...

Immunology pipeline: New data from Sanofi’s immunology pipeline will be featured, including new analyses evaluating rilzabrutinib in moderate-to-severe asthma, and transcriptomic data in patients with ...

A new study published in the Journal of American Medical Association showed that Rilzabrutinib decreased itching and hives while preserving a positive risk-benefit profile, indicating that it might be ...

(IN BRIEF) Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in consumer healthcare. Sanofi retains a ...

CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of hives, angioedema, or both, lasting more than six weeks without an ...

Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...